digital health companies weight loss glp-1 👎 The startup making look bad Miami's eMed just hit a

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

Learn dosing protocols, which conditions respond, mechanisms, and what research supports.

How GLP-1 drugs ease joint pain and inflammation in RA, psoriatic arthritis, osteoarthritis, lupus, gout.

Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.

Brands that advertise access to weight loss drugs will want to develop messaging for when appointments surge

Get Lexapro prescribed online by a caring, board-certified doctor online.